Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Pelletier, J. (Jean)"'
Autor:
Sormani, M. (Maria Pia) P. (P), Salvetti, M. (Marco), Labauge, P. (Pierre), Schiavetti, I. (Irene), Zephir, H. (Helene), Carmisciano, L. (Luca), Bensa, C. (Caroline), De Rossi, N. (Nicola), Pelletier, J. (Jean), Cordioli, C. (Cinzia), Vukusic, S. (Sandra), Moiola, L. (Lucia), Kerschen, P. (Philippe), Radaelli, M. (Marta), Théaudin, M. (Marie), Immovilli, P. (Paolo), Casez, O. (Olivier), Capobianco, M. (Marco), Ciron, J. (Jonathan), Trojano, M. (Maria), Stankoff, B. (Bruno), Créange, A. (Alain), Tedeschi, G. (Gioacchino), Clavelou, P. (Pierre), Comi, G. (Giancarlo), Thouvenot, E. (Eric), Battaglia, M. (Mario) A. (Alberto), Moreau, T. (Thibault), Patti, F. (Francesco), De Sèze, J. (Jérôme), Louapre, C. (Celine), Musc
We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4060::dc37d5ee56459d01d00b19c2d0d35639
Autor:
Veillard, D. (David), Baumstarck, K. (Karine), Edan, G. (Gilles), Debouverie, M. (Marc), Wiertlewski, S. (Sandrine), De Sèze, J. (Jérôme), Clavelou, P. (Pierre), Pelletier, J. (Jean), Verny, C. (Christophe), Chauvin, K. (Karine), Cosson, M. (Marie Elisabeth) E. (E), Loundou, A. (Anderson), Auquier, P. (Pascal)
BACKGROUND AND PURPOSE: Patients with a chronic illness, such as multiple sclerosis (MS), and their natural caregivers have a specific experience of healthcare and health services. These experiences need to be assessed to evaluate the quality of care
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4060::f0628796da271fe7e3f17018d33e12a9
Autor:
Ayrignac, X. (Xavier), Bigaut, K. (Kévin), Pelletier, J. (Jean), De Sèze, J. (Jérôme), Demortiere, S. (Sarah), Collongues, N. (Nicolas), Maarouf, A. (Adil), Pinna, F. (Frédéric), Aouinti, S. (Safa), Carra Dallière, C. (Clarisse), Kremer, L. (Laurent), Charif, M. (Mahmoud), Picot, M. (Marie) C. (Christine), Labauge, P. (Pierre)
BACKGROUND: The advent of new, potent, disease-modifying therapies has dramatically changed the management of multiple sclerosis (MS). Along with these possibilities, it is crucial to better recognize patients who are at risk of first line treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4060::2176977fb91cde98c785dad1bdf7d31a
Autor:
Louapre, C. (Céline), Collongues, N. (Nicolas), Stankoff, B. (Bruno), Giannesini, C. (Claire), Papeix, C. (Caroline), Bensa, C. (Caroline), Deschamps, R. (Romain), Créange, A. (Alain), Wahab, A. (Abir), Pelletier, J. (Jean), Heinzlef, O. (Olivier), Labauge, P. (Pierre), Guilloton, L. (Laurent), Ahle, G. (Guido), Goudot, M. (Mathilde), Bigaut, K. (Kevin), Laplaud, D. (David-Axel), Vukusic, S. (Sandra), Lubetzki, C. (Catherine), De Sèze, J. (Jérôme)
Importance: Risk factors associated with the severity of coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (MS) are unknown. Disease-modifying therapies (DMTs) may modify the risk of developing a severe COVID-19 infection, besid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4060::90c840efb19bc53ff3430b925aba1c27
Autor:
Barbin, L. (Laetitia), Rousseau, C. (Chloe), Jousset, N. (Natacha), Casey, R. (Romain), Debouverie, M. (Marc), Vukusic, S. (Sandra), De Seze, J. (Jerome), Brassat, D. (David), Wiertlewski, S. (Sandrine), Brochet, B. (Bruno), Pelletier, J. (Jean), Vermersch, P. (Patrick), Edan, G. (Gilles), Lebrun-Frenay, C. (Christine), Clavelou, P. (Pierre), Thouvenot, E. (Eric), Camdessanché, J. (Jean-Philippe), Tourbah, A. (Ayman), Stankoff, B. (Bruno), Al Khedr, A. (Abdullatif), Cabre, P. (Philippe), Papeix, C. (Caroline), Berger, E. (Eric), Heinzlef, O. (Olivier), Debroucker, T. (Thomas), Moreau, T. (Thibault), Gout, O. (Olivier), Bourre, B. (Bertrand), Créange, A. (Alain), Labauge, P. (Pierre), Magy, L. (Laurent), Defer, G. (Gilles), Foucher, Y. (Yohann), Laplaud, D. (David A), CFSEP and OFSEP groups
Publikováno v:
Neurology
Neurology, 2016, 86 (8), pp.771-778. ⟨10.1212/WNL.0000000000002395⟩
Neurology, American Academy of Neurology, 2016, 86 (8), pp.771-778. ⟨10.1212/WNL.0000000000002395⟩
Neurology, 2016, 86 (8), pp.771-778. ⟨10.1212/WNL.0000000000002395⟩
Neurology, American Academy of Neurology, 2016, 86 (8), pp.771-778. ⟨10.1212/WNL.0000000000002395⟩
OBJECTIVE: To compare natalizumab and fingolimod on both clinical and MRI outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) from 27 multiple sclerosis centers participating in the French follow-up cohort Observatoire of Multiple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c73a86ed2bee10e58974c4f61412e182
https://doi.org/10.1212/WNL.0000000000002395
https://doi.org/10.1212/WNL.0000000000002395